OCUL (Ocular Therapeutix) Cyclically Adjusted Book per Share: $1.40 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCUL Ocular Therapeutix Inc OCUL
55 GF Score
Price $11.47
GF Value $4.56
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ocular Therapeutix Cyclically Adjusted Book per Share?

Ocular Therapeutix OCUL -2.30% 55 Cyclically Adjusted Book per Share is $1.40 as of Jun. 2026. GuruFocus rates OCUL with a GF Score™ of 55/100 and a GF Value™ of $4.56 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ocular Therapeutix's adjusted book value per share for the three months ended in Jun. 2026 was $2.368. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.40 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Ocular Therapeutix's average Cyclically Adjusted Book Growth Rate was -11.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ocular Therapeutix was -0.20% per year. The lowest was -0.20% per year. And the median was -0.20% per year.

As of today (2026-08-20), Ocular Therapeutix's current stock price is $11.47. Ocular Therapeutix's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $1.40. Ocular Therapeutix's Cyclically Adjusted PB Ratio of today is 8.19.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ocular Therapeutix was 9.77. The lowest was 1.50. And the median was 4.67.


Ocular Therapeutix  (NAS:OCUL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ocular Therapeutix's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.47/1.40
=8.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ocular Therapeutix was 9.77. The lowest was 1.50. And the median was 4.67.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ocular Therapeutix Cyclically Adjusted Book per Share Related Terms


Ocular Therapeutix Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Cyclically Adjusted Book per Share Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.45 1.51 1.69 1.44

Ocular Therapeutix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 1.49 1.44 1.42 1.40

OCUL vs KARD, GHRS, FTRE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted PB Ratio falls into.


OCUL
55GF Score
Ocular Therapeutix Inc OCUL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocular Therapeutix's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.368/333.9520*333.9520
=2.368

Current CPI (Jun. 2026) = 333.9520.

Ocular Therapeutix Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.504 241.428 3.464
201612 2.078 241.432 2.874
201703 2.209 243.801 3.026
201706 1.653 244.955 2.254
201709 1.222 246.819 1.653
201712 0.882 246.524 1.195
201803 1.319 249.554 1.765
201806 1.188 251.989 1.574
201809 1.123 252.439 1.486
201812 0.864 251.233 1.148
201903 0.599 254.202 0.787
201906 0.187 256.143 0.244
201909 0.235 256.759 0.306
201912 -0.072 256.974 -0.094
202003 -0.201 258.115 -0.260
202006 0.085 257.797 0.110
202009 -0.065 260.280 -0.083
202012 1.001 260.474 1.283
202103 1.094 264.877 1.379
202106 1.050 271.696 1.291
202109 1.140 274.310 1.388
202112 1.147 278.802 1.374
202203 1.040 287.504 1.208
202206 0.856 296.311 0.965
202209 0.600 296.808 0.675
202212 0.458 296.797 0.515
202303 0.125 301.836 0.138
202306 0.039 305.109 0.043
202309 0.099 307.789 0.107
202312 0.793 306.746 0.863
202403 2.637 312.332 2.820
202406 2.427 314.175 2.580
202409 2.247 315.301 2.380
202412 1.999 315.605 2.115
202503 1.670 319.799 1.744
202506 1.769 322.561 1.831
202509 1.476 324.800 1.518
202512 3.030 324.054 3.123
202603 2.657 330.213 2.687
202606 2.368 333.952 2.368

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.40 mean?
Ocular Therapeutix (OCUL) has a Cyclically Adjusted Book per Share of $1.40 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors.
Is Ocular Therapeutix's Cyclically Adjusted Book per Share too high?
Ocular Therapeutix's current Cyclically Adjusted Book per Share is $1.40. Overall, Ocular Therapeutix has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Cyclically Adjusted Book per Share compare to KARD and GHRS?
Ocular Therapeutix's Cyclically Adjusted Book per Share of $1.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current Cyclically Adjusted Book per Share is $1.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.56, compared to a current price of $11.47 — trading 151.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.40. Ocular Therapeutix's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current Cyclically Adjusted Book per Share is $1.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (OCUL) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of $11.47 is trading 151.5% above its estimated GF Value™ of $4.56. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for OCUL:

  • Cyclically Adjusted Book per Share: $1.40
  • GF Value™: $4.56 vs. price of $11.47 (151.5% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges 0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
55GF Score

Get the complete analysis for OCUL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.47
Price
$4.56
GF Value